News: GlaxoSmithKline PLC (GSK.N)

GSK.N on New York Stock Exchange

42.04USD
17 Dec 2014
Price Change (% chg)

$0.12 (+0.29%)
Prev Close
$41.92
Open
$41.92
Day's High
$42.29
Day's Low
$41.73
Volume
676,930
Avg. Vol
927,801
52-wk High
$56.73
52-wk Low
$41.29

Search Stocks
Select another date:

Fitch Affirms GlaxoSmithKline PLC at 'A+'; Revises Outlook to Negative

(The following statement was released by the rating agency) LONDON, December 17 (Fitch) Fitch Ratings has affirmed UK-based pharmaceuticals company GlaxoSmithKline PLC's (GSK) Long-term Issuer Default Rating (IDR) and senior unsecured rating at 'A+'. The Outlook has been revised to Negative from Stable. Fitch has also affirmed the senior unsecured rating of 'A+' for the debt issued under GlaxoSmithKline Capital PLC. The Negative Outlook encapsulates Fitch's expectation of increasing financia

Antibiotic developer Cempra's CEO says not looking for a buyer

- Cempra Inc has no plans for now to sell itself, its CEO said, brushing off talk that the company is a potential target as big drugmakers set their sights on antibiotic developers.

BRIEF-GSK files regulatory submission for variation to marketing authorisation for Ambrisentan

* GSK press release: GSK announces EU regulatory submission seeking extended indication for Ambrisentan (Volibris) in pulmonary arterial hypertension

One shot or two? Many questions unresolved in Ebola vaccine race

* Debate over "prime-boost" vaccination as epidemic evolves

BRIEF-Aspen Pharmacare director Abbas Hussain resigns

* Abbas Hussain has confirmed that he intends to tender his resignation as a director of company with effect from Feb. 1 2015

Merck to take on superbugs with Cubist Pharma buy

- Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.

UPDATE 4-Merck to take on superbugs with Cubist Pharma buy

* Merck to pay $8.4 bln, plus assumption of $1.1 bln of debt

Deals of the day- Mergers and acquisitions

(Adds GSK, Enbridge, Barnes & Noble, Dollar General, Budapest Bank, Songbird Estates, Unilever, New York Life Insurance Co; updates Orange, Technip)

GlaxoSmithKline drops plan to sell off older drugs business

LONDON - GlaxoSmithKline said on Thursday it had decided not to sell a portfolio of older drugs marketed in North America and Europe after considering offers from potential buyers.

GlaxoSmithKline drops plan to sell off older drugs business

LONDON - GlaxoSmithKline said on Thursday it had decided not to sell a portfolio of older drugs marketed in North America and Europe after considering offers from potential buyers.

Select another date:

Press Releases

Search Stocks